CCND2 and Miyoshi myopathy: The results indicated that induced overexpression of cyclin D2 compensated for the loss of cyclin D1 and promoted trametinib resistance in otherwise treatment-sensitive M5 MM cells, which lacked an intrinsic capacity to upregulate endogenous cyclin D2 in response to trametinib (Figure 3A).